Valneva shares slump after the companies said the study's primary endpoint didn't meet statistical significance Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine.

Dec 9 (Reuters) - Pfizer said ‌on Tuesday it ‌had entered into an ⁠exclusive ‌licensing agreement with ‍YaoPharma, a subsidiary of Shanghai Fosun ‌Pharmaceutical, for the development and ...

(Bloomberg) -- Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...

Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers.

HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for ...

Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...

TRENTON, N.J. (AP) -- The drugmaker Pfizer Inc. and nearly a dozen health advocacy groups want to help senior citizens and younger people talk about a subject many find frightening or at least ...

Pharmaceutical giant Pfizer and French partner Valneva said they plan to seek regulatory approval for a Lyme disease vaccine after sharing mixed results from a late-stage trial. The companies said ...